These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 28398199)

  • 1. Wasp Venom Immunotherapy in a Patient With Immune-Mediated Inflammatory Central Nervous System Disease: Is it Safe?
    Nittner-Marszalska M; Kowal A; Szewczyk P; Guranski K; Ejma M
    J Investig Allergol Clin Immunol; 2017; 27(2):127-129. PubMed ID: 28398199
    [No Abstract]   [Full Text] [Related]  

  • 2. Pre-emptive Evaluation of Venom Allergy in a Patient with Systemic Mastocytosis.
    Gülen T; Akin C
    Acta Derm Venereol; 2018 Jan; 98(1):149-150. PubMed ID: 28902950
    [No Abstract]   [Full Text] [Related]  

  • 3. Rush immunotherapy for wasp venom allergy seems safe and effective in patients with mastocytosis.
    Verburg M; Oldhoff JM; Klemans RJ; Lahey-de Boer A; de Bruin-Weller MS; Röckmann H; Sanders C; Bruijnzeel-Koomen CA; Pasmans SG; Knulst AC
    Eur Ann Allergy Clin Immunol; 2015 Nov; 47(6):192-6. PubMed ID: 26549336
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Initiating yellow jacket venom immunotherapy with a 100-μg dose: A challenge?
    Vos BJPR; Dubois AEJ; Rauber MM; Pfützner W; Miehe M; Bohle B; Möbs C; Oude Elberink JNG
    J Allergy Clin Immunol Pract; 2019 Apr; 7(4):1332-1334.e4. PubMed ID: 30240885
    [No Abstract]   [Full Text] [Related]  

  • 5. Successful venom immunotherapy to paper wasp, in IgE-venom negative patient.
    Vovolis V; Mikos N; Koutsostathis N
    Allergol Immunopathol (Madr); 2011; 39(1):57-8. PubMed ID: 20655651
    [No Abstract]   [Full Text] [Related]  

  • 6. Safety of Ultrarush Venom Immunotherapy: Comparison Between Children and Adults.
    Nittner-Marszalska M; Cichocka-Jarosz E; Małaczyńska T; Kraluk B; Rosiek-Biegus M; Kosinska M; Pawłowicz R; Lis G
    J Investig Allergol Clin Immunol; 2016; 26(1):40-7. PubMed ID: 27012015
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Wasp allergy vaccination].
    Røsjø HR; Hov JE; Borchsenius F; Skjønsberg OH
    Tidsskr Nor Laegeforen; 2003 Apr; 123(8):1075-7. PubMed ID: 12760227
    [No Abstract]   [Full Text] [Related]  

  • 8. Anaphylaxis after hymenoptera sting: is it venom allergy, a clonal disorder, or both?
    Castells MC; Hornick JL; Akin C
    J Allergy Clin Immunol Pract; 2015; 3(3):350-5. PubMed ID: 25858055
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sublingual immunotherapy with venom for patients with Hymenoptera venom allergy.
    Patriarca G; Nucera E; Roncallo C; Aruanno A; Lombardo C; Decinti M; Pascolini L; Milani M; Buonomo A; Schiavino D
    J Allergy Clin Immunol; 2009 Aug; 124(2):385; author reply 385-6. PubMed ID: 19482349
    [No Abstract]   [Full Text] [Related]  

  • 10. [Fatal reaction to wasp sting in a patient allergic to wasp venom].
    Mark CK; Grøfte T; Shim J
    Ugeskr Laeger; 2015 Apr; 177(17):. PubMed ID: 25922165
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discontinuation of venom immunotherapy.
    Golden DB
    J Allergy Clin Immunol; 1998 Oct; 102(4 Pt 1):703-4. PubMed ID: 9802387
    [No Abstract]   [Full Text] [Related]  

  • 12. Venom immunotherapy (VIT): clinical efficacy and improvement in quality of life.
    Oude Elberink J
    Drugs Today (Barc); 2008 Dec; 44 Suppl B():43-5. PubMed ID: 19221618
    [No Abstract]   [Full Text] [Related]  

  • 13. Honeybee and wasp venom allergy: Sensitization and immunotherapy.
    Adib-Tezer H; Bayerl C
    J Dtsch Dermatol Ges; 2018 Oct; 16(10):1228-1247. PubMed ID: 30300499
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Therapy control of specific hymenoptera venom allergy].
    Aust W; Wichmann G; Dietz A
    Laryngorhinootologie; 2010 Dec; 89(12):725-8. PubMed ID: 21132618
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Is desensitization always indicated in allergy to insect venoms?].
    Prybilla B; Ruëff F
    Dtsch Med Wochenschr; 1994 Aug; 119(31-32):1093-5. PubMed ID: 8055747
    [No Abstract]   [Full Text] [Related]  

  • 16. Analysis of safety, risk factors and pretreatment methods during rush hymenoptera venom immunotherapy.
    Gorska L; Chelminska M; Kuziemski K; Skrzypski M; Niedoszytko M; Damps-Konstanska I; Szymanowska A; Siemińska A; Wajda B; Drozdowska A; Jutel M; Jassem E
    Int Arch Allergy Immunol; 2008; 147(3):241-5. PubMed ID: 18594155
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Results of hyposensitization with bee and wasp venom].
    Adolph J; Dehnert I; Fischer JF; Wenz W
    Z Erkr Atmungsorgane; 1986; 166(1):119-24. PubMed ID: 3953108
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expanding indications of omalizumab therapy in the absence of specific IgE.
    Khan S; Deacock S
    Allergol Immunopathol (Madr); 2011; 39(3):189. PubMed ID: 21470760
    [No Abstract]   [Full Text] [Related]  

  • 19. The safety of initiating Hymenoptera immunotherapy at 1 microg of venom extract.
    Roumana A; Pitsios C; Vartholomaios S; Kompoti E; Kontou-Fili K
    J Allergy Clin Immunol; 2009 Aug; 124(2):379-81. PubMed ID: 19560804
    [No Abstract]   [Full Text] [Related]  

  • 20. [Bee and wasp venom allergy].
    Przybilla B
    HNO; 1995 Jul; 43(7):451-62. PubMed ID: 7673005
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.